← Leaderboards
Lapo Alinari
Ohio State University
$4,506,413
Attributed
$5,704,650
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,704,650 · 5
By mechanism
R01$4,070,536 · 2
K08$1,135,230 · 1
P30$498,884 · 2
Top collaborators
- Marcos De Lima3 shared
- Sumithira Vasu3 shared
Most similar at Ohio State University
Same institution · by research overlap
- Steven K Clinton$5,749,067
- David P Carbone$20,647,321
- David Matthew Lucas$355,169
- Sherif S Farag$9,761,380
- Michael C Ostrowski$13,472,116
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsLymphomaProgramsGeneticCell SurvivalFundingOhioClinical TrialsUniversitiesImmuneRelapseResponsePre-Clinical ModelNovel Therapeutic InterventionMediatingCellsRefractoryGenetic TranscriptionInstitutionGrantGenomicsHematologyRecruitClinic
Grant awards (17)
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$609,273
R01 · FY2025 · CA
Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma$570,593
R01 · FY2025 · CA · contact PI
Shared Resource 09: Leukemia Tissue Bank (LTBSR)$98,422
P30 · FY2025 · CA · contact PI
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$578,809
R01 · FY2024 · CA
Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma$542,063
R01 · FY2024 · CA · contact PI
Shared Resource 09: Leukemia Tissue Bank (LTBSR)$100,114
P30 · FY2024 · CA · contact PI
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$609,273
R01 · FY2023 · CA
Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma$559,179
R01 · FY2023 · CA · contact PI
Shared Resource 09: Leukemia Tissue Bank (LTBSR)$100,116
P30 · FY2023 · CA · contact PI
Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma$601,346
R01 · FY2022 · CA · contact PI
Targeting transducin Beta-like protein 1 in mantle cell lymphoma$227,046
K08 · FY2022 · CA · contact PI
Shared Resource 09: Leukemia Tissue Bank (LTBSR)$100,116
P30 · FY2022 · CA · contact PI
Targeting transducin Beta-like protein 1 in mantle cell lymphoma$227,046
K08 · FY2021 · CA · contact PI
Shared Resource 09: Leukemia Tissue Bank (LTBSR)$100,116
P30 · FY2021 · CA · contact PI
Targeting transducin Beta-like protein 1 in mantle cell lymphoma$227,046
K08 · FY2020 · CA · contact PI
Targeting transducin Beta-like protein 1 in mantle cell lymphoma$227,046
K08 · FY2019 · CA · contact PI
Targeting transducin Beta-like protein 1 in mantle cell lymphoma$227,046
K08 · FY2018 · CA · contact PI